Reimbursement Review Reports


( Last Updated : April 2, 2015)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort ascending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Zytram XL Tramadol hydrochloride Pain, acute Withdrawn
Zytram XL Tramadol hydrochloride Pain, acute Do not list Complete
Zytiga (Resubmission) Abiraterone Prostate Cancer Resubmission Withdrawn
Zytiga Abiraterone acetate Metastatic Castration Resistant Prostate Cancer Reimburse with clinical criteria and/or conditions Complete
Zytiga Abiraterone Withdrawn
Zykadia (Resubmission) Ceritinib metastatic non-small cell lung cancer Reimburse with clinical criteria and/or conditions Complete
Zykadia Ceritinib Metastatic Non-Small Cell Lung Cancer Do not reimburse Complete
Zydelig Idelalisib Chronic lymphocytic leukemia Reimburse with clinical criteria and/or conditions Complete
Zydelig Idelalisib Follicular Lymphoma Do not reimburse Complete
Zolinza vorinostat Cutaneous T-cell lymphoma CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed